Sodium Fluorescein

DRUG6 trials

Sponsors

Bausch & Lomb Incorporated, Cecilia Calvo, Columbia University, University Hospitals Cleveland Medical Center, University of Colorado, Denver

Conditions

HyperemiaInjury of UreterPediatric Neurosurgical TumorsUreteral InjuryUreteral Patency

Phase 3

Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

CompletedNCT01959243

Bausch & Lomb IncorporatedHyperemia

Start: 2014-02-22End: 2014-06-23Updated: 2019-10-23

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

CompletedNCT01959230

Bausch & Lomb IncorporatedHyperemia

Start: 2013-11-07End: 2013-12-20Updated: 2019-10-23

Phase 4

Evaluation of Ureteral Patency in the Post-indigo Carmine Era

CompletedNCT02677623

Columbia UniversityUreteral Patency

Start: 2015-03-31End: 2016-08-31Updated: 2019-05-30

Unknown Phase

Evaluation of Ureteral Jets on Cystoscopy

CompletedNCT02476448

Cecilia CalvoInjury of Ureter

Start: 2015-02-28End: 2016-07-31Updated: 2019-10-23

Intravenous Sodium Fluorescein Versus Oral Phenazopyridine for Ureteral Patency

WithdrawnNCT02757417

University Hospitals Cleveland Medical CenterUreteral Injury

Start: 2016-07-31End: 2019-12-31Updated: 2022-05-06

Sodium Fluorescein-Guided Resection of Pediatric Neurosurgical Tumors

TerminatedNCT03752203

University of Colorado, DenverPediatric Neurosurgical Tumors

Start: 2021-08-11End: 2023-06-29Updated: 2025-03-06

Related Papers

Intraoperative Cystoscopic Evaluation of Ureteral Patency

Obstetrics and Gynecology2016-11-0830 citations